Rimonci Capital

TECLens, LLC is a development stage company based in St. James, New York, focused on designing and manufacturing medical contact lenses for myopia treatment. Established in 2013, the company has developed a non-invasive therapy involving the use of its product, the CXLens (Corneal Crosslinking Lens), which is worn for just half an hour in a doctor's office. This innovative lens features real-time ultrasound sensing and a high oxygen concentration environment to ensure precise targeting and stability during treatment. TECLens aims to address various vision issues, including progressive myopia in children and vision problems in adults, such as hyperopia and low-order myopia. Its technology is designed to improve patients' eye health and potentially reduce the long-term risks associated with traditional corrective lenses.

Laclarée Vision specializes in the development of adaptive eyeglasses designed to correct presbyopia. Founded in 2016 and based in Lyon, France, the company utilizes patented fluid technology to create lenses that automatically adjust in real-time to various viewing distances. This innovative approach addresses the needs of individuals aged 45 and older who often find traditional solutions, such as progressive lenses or multiple pairs of glasses, unsatisfactory. By combining adaptive lens technology with refractive correction for conditions like astigmatism, myopia, and hyperopia, Laclarée aims to provide a clearer vision experience for its users.

EyeYon Medical Ltd. is an Israeli company specializing in the development of medical devices for the treatment of corneal edema. Founded by a team of experienced professionals in ophthalmology and business, the company is based in Jerusalem and operates within the Van Leer Technology Incubator. Its key products include Hyper-CL, a hyperosmotic contact lens that utilizes osmosis to extract fluids from corneal edema, thereby improving vision and alleviating pain. Additionally, EyeYon Medical offers DSPEK, an artificial endothelial layer designed to replace damaged endothelial tissue, which is crucial in cases of corneal edema. The company's innovative solutions are non-invasive, comfortable, and facilitate effective eye care for patients dealing with both acute and chronic ocular conditions.

EyeControl is a pioneer in medical technology focused on innovative communication solutions for healthcare. The company has developed a unique device aimed at improving the quality of life for patients with locked-in syndrome, particularly those suffering from ALS. This device consists of a simple glass frame equipped with an infrared camera that connects to a compact computer. It translates the patients' blinks and eye movements into commands, which are then converted into speech through earphones and a speaker. By leveraging advanced technology, EyeControl addresses significant communication barriers, enabling patients to express their needs and preferences more effectively.

BELKIN Vision focuses on developing a laser device that aids healthcare professionals in the treatment of glaucoma. The company's technology offers a non-invasive, non-contact, instantaneous, painless, and automated approach to laser therapy. By promoting accessibility to first-line drop-less glaucoma care, BELKIN Vision enables any ophthalmologist to effectively treat patients. This innovation aims to enhance treatment outcomes and improve the overall quality of care for individuals suffering from glaucoma.

NovaSight Ltd, founded in 2016 and based in Israel, specializes in pediatric vision care through the development of CureSight, an innovative eye-tracking system for treating amblyopia. The company focuses on integrating digital solutions for accurate vision assessment and efficient treatment tailored to the specific needs and attention spans of children. By utilizing eye-tracking technology, NovaSight aims to prevent vision impairments in pediatric patients through novel diagnostic, therapeutic, and preventive approaches. Its management team and scientific advisory board consist of experienced professionals and leaders in pediatric vision care, ensuring a strong foundation for advancing vision health in children.

6over6 is a digital healthcare company that has created a platform allowing users to conduct their own eye vision tests using their smartphones. The platform integrates essential optometric tools to accurately measure the refractive error of the eye, facilitating the prescription of eyeglasses and contact lenses. By utilizing software to retrieve optical parameters from existing eyewear, 6over6 aims to make vision care more accessible. Their product, GlassesOn, is registered as a Class 1 Exempt Medical Device with the FDA. However, it is important to note that GlassesOn does not offer medical advice and is not a substitute for a comprehensive eye health examination.

BELKIN Vision focuses on developing a laser device that aids healthcare professionals in the treatment of glaucoma. The company's technology offers a non-invasive, non-contact, instantaneous, painless, and automated approach to laser therapy. By promoting accessibility to first-line drop-less glaucoma care, BELKIN Vision enables any ophthalmologist to effectively treat patients. This innovation aims to enhance treatment outcomes and improve the overall quality of care for individuals suffering from glaucoma.

EyeYon Medical Ltd. is an Israeli company specializing in the development of medical devices for the treatment of corneal edema. Founded by a team of experienced professionals in ophthalmology and business, the company is based in Jerusalem and operates within the Van Leer Technology Incubator. Its key products include Hyper-CL, a hyperosmotic contact lens that utilizes osmosis to extract fluids from corneal edema, thereby improving vision and alleviating pain. Additionally, EyeYon Medical offers DSPEK, an artificial endothelial layer designed to replace damaged endothelial tissue, which is crucial in cases of corneal edema. The company's innovative solutions are non-invasive, comfortable, and facilitate effective eye care for patients dealing with both acute and chronic ocular conditions.